Sign in
Not yet recruitingPhase 4

Fecal Molecular Susceptibility-guided Hp Rescue Therapy

Key facts

Who runs it
Shanghai Zhongshan Hospital
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
290 people, planned
Started
28 Feb 2026
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 7-day fecal molecular susceptibility-guided therapy
  • 14-day fecal molecular susceptibility-guided therapy
Record updated
12 February 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Voluntarily participate in this clinical study; fully understand, be informed about this study, and sign the Informed Consent Form (ICF)
  • Age between 18 and 75 years (inclusive) on the day of signing the ICF
  • 13C-urea breath test (13C-UBT) and fecal HP nucleic acid detection confirming Helicobacter pylori (Hp) infection
  • previously eradicated HP

Who cannot take part

  • Alcohol and/or drug abuse (dependence or addiction) or individuals judged by the physician to have poor compliance
  • Use of antibiotics, bismuth-containing drugs, PPIs, or traditional Chinese medicines within 4 weeks before treatment
  • Individuals with a known allergy to the medication
  • Patients with severe cardiovascular, pulmonary, renal, hepatic, hematologic, neurologic, endocrine, or psychiatric disorders
  • Any condition deemed by the investigator to be unsuitable for enrollment
  • Participants or guardians who refuse to enroll
  • Pregnant or lactating women

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the eradication efficacy and health economic benefits of individualized regimens guided by fecal molecular susceptibility testing with 7-day and 14-day courses in the rescue treatment of Helicobacter pylori infection. The main questions it aims to answer are:

Read full original descriptionShow less

1. What is the H. pylori eradication rate of the 7-day versus 14-day individualized regimens? 2. What are the safety, adherence, and cost-effectiveness of the 7-day versus 14-day individualized regimens? Researchers will compare the 7-day course group and the 14-day course group to see if the 7-day course is non-inferior to the 14-day course in terms of eradication rate.

Participants will:

1. Undergo fecal H. pylori drug resistance gene testing 2. Receive randomized assignment to either 7-day or 14-day individualized treatment based on drug susceptibility results 3. Complete follow-up visits at 1 week and 4-8 weeks after stopping treatment for adverse event monitoring and 13C-urea breath test

The 2 groups in the trial

  • 7-dayTreatment being tested

    7-day fecal molecular susceptibility-guided therapy

    Treatment: 7-day fecal molecular susceptibility-guided therapy

  • 14-dayExisting treatment, for comparison

    14-day fecal molecular susceptibility-guided therapy

    Treatment: 14-day fecal molecular susceptibility-guided therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Efficacy and Health Economic Evaluation of Fecal Molecular Susceptibility-guided Therapy for Helicobacter Pylori Infection Rescue Treatment: Multicenter Randomized Controlled Study
Criteria questions
Built from NCT07405697, who can take part
Record updated
12 February 2026